NTLA Latest Headlines

FDA Clears Path for Intellia’s MAGNITUDE-2 Trial—Enrollment Resumes for Promising One-Time Therapy

Market Chameleon (Tue, 27-Jan 8:21 AM)

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

at www.tipranks.com (Tue, 27-Jan 11:46 AM)

Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Safety Freeze on Nerve Disease Trial

at www.tipranks.com (Tue, 27-Jan 10:15 AM)

Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Saftey Freeze on Nerve Disease Trial

at www.tipranks.com (Tue, 27-Jan 10:15 AM)

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Opus Genetics (IRD) and Argenx Se (ARGX)

at www.tipranks.com (Tue, 27-Jan 10:00 AM)

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Cardiff Oncology (CRDF)

at www.tipranks.com (Tue, 27-Jan 9:50 AM)

FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial

at www.tipranks.com (Tue, 27-Jan 8:49 AM)

Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug

at seekingalpha.com (Tue, 27-Jan 8:31 AM)

NTLA Sets the Stage for 2026 with High-Profile J.P. Morgan Healthcare Conference Presentation

Market Chameleon (Wed, 7-Jan 8:41 AM)

Intellia Therapeutics Awards 22,800 RSUs as Inducement Grants to New Hires—What This Signals for NTLA’s Talent Strategy

Market Chameleon (Mon, 5-Jan 8:44 AM)

Intellia Awards Inducement Grants: 12,600 RSUs Allocated to New Hires Under 2024 Plan

Market Chameleon (Mon, 8-Dec 8:25 AM)

NTLA: One-Time CRISPR Treatment Shows 97% Attack-Free Rate for Hereditary Angioedema Patients

Market Chameleon (Mon, 10-Nov 7:06 AM)